Pharmacokinetics of Daprodustat and Metabolites in Individuals with Normal and Impaired Hepatic Function-Reference-Cited by-同舟云学术

Pharmacokinetics of Daprodustat and Metabolites in Individuals with Normal and Impaired Hepatic Function

Published:2022-03-30 Issue:5 Volume:11 Page:562-575
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharm in Drug Dev

Author:

Mahar Kelly M.¹,Shaddinger Bonnie C.²,Ramanjineyulu Bandi³,Andrews Susan⁴,Caltabiano Stephen²,Lindsay Alistair C.²,Cobitz Alexander R.²

Affiliation:

1. Clinical Pharmacology Modeling & Simulation GlaxoSmithKline Collegeville Pennsylvania USA

2. Medicine Delivery Unit GlaxoSmithKline Collegeville Pennsylvania USA

3. Biostatistics GlaxoSmithKline Bangalore India

4. Clinical Science & Study Operations GlaxoSmithKline Collegeville Pennsylvania USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.1090

Reference26 articles.

1. Mechanisms of Anemia in CKD

2. The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients

3. KDIGO clinical practice guideline for anemia in chronic kidney disease;Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group;Kidney Int Suppl,2012

4. Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018

5. A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrated Population Pharmacokinetics of Daprodustat in Patients with Chronic Kidney Disease with Anemia;Clinical Pharmacokinetics;2024-09-11

2. The mechanism of action and chemical synthesis of FDA newly approved drug molecules;Drug Development Research;2024-09

3. The drug-specific properties of hypoxia-inducible factor-prolyl hydroxylase inhibitors in mice reveal a significant contribution of the kidney compared to the liver to erythropoietin induction;Life Sciences;2024-06

4. Mechanistic Determinants of Daprodustat Drug–Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B‐CYP2C8 Interplay;Clinical Pharmacology & Therapeutics;2024-02-26

5. Daprodustat;Hospital Pharmacy;2023-05-17